Anti-TNF Treatment in Crohn's Disease: Toward Tailored Therapy?

D’Haens, Geert R.

doi:10.1038/ajg.2010.15

Cited by 8 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is now known that tumor necrosis factor (TNF)‐α plays an important role in the pathogenesis of mucosal inflammation in CD. Therefore, biological agents are widely used in patients who do not respond to conventional therapy 5 . Adalimumab, which was constructed from a fully human monoclonal antibody (immunoglobulin G1) to TNF, is delivered s.c.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of adalimumab in Crohn's disease: Meta‐analysis of placebo‐controlled trials

Huang

Ran

Shen

et al. 2011

J of Digest Diseases

View full text Add to dashboard Cite

OBJECTIVE: To evaluate the efficacy and safety of adalimumab in inducing and maintaining remission of Crohn's disease. METHODS: Electronic databases were searched. Placebo‐controlled trials of adalimumab used in patients with Crohn's disease were included. Data were analyzed with Review Manager 4.2. RESULTS: Four studies enrolling 1402 patients were confirmed as meeting our criteria. Remission rates of inducing and maintaining remission in patients with Crohn's disease were higher for adalimumab than placebo (P < 0.05). Adalimumab significantly improves the quality of life in patients with Crohn's disease. No significant difference in total adverse events was found in maintaining remission. Moreover, there were significantly less serious adverse events from taking adalimumab than from taking the placebo in long‐term treatment. Patients with increased baseline C‐reactive protein may benefit more from adalimumab therapy than those without. CONCLUSIONS: Adalimumab is effective and safe in Crohn's disease. However, studies of a larger number of patients are still required for better assessing the safety profile of adalimumab.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Therefore, biological agents are widely used in patients who do not respond to conventional therapy. 5 Adalimumab, which was constructed from a fully human monoclonal antibody (immunoglobulin G1) to TNF, is delivered s.c. Currently it is used for induction and maintenance therapy in moderate to severe CD.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of adalimumab in Crohn's disease: Meta‐analysis of placebo‐controlled trials

Huang

Ran

Shen

et al. 2011

J of Digest Diseases

View full text Add to dashboard Cite

show abstract

“…Tumor necrosis factor (TNF)␣ is found to play an important role in the pathogenesis of IBD based on the fact that administration of anti-TNF␣ can significantly ameliorate the pathogenesis of IBD (4). Recent advances also indicate that interleukin (IL)-23, mainly produced by macrophages, is one of the critical cytokines in IBD and is essential for promoting chronic intestinal inflammation (5,6).…”

Section: Interleukin (Il)mentioning

confidence: 99%

Interleukin (IL)-23 Suppresses IL-10 in Inflammatory Bowel Disease

Liu

Feng

Yang

et al. 2012

Journal of Biological Chemistry

View full text Add to dashboard Cite

show abstract

“…Detectable ATI is associated with a reduced duration of clinical response and an increased risk of infusion reactions 8, 10, 13, 16, 17. ATI that bind and inactivate infliximab compound may decrease the biologically active infliximab level10, 18 and have been associated with low detectable trough serum levels of infliximab (i.e., measured before the next infusion) in IBD patients 8, 16, 19–21…”

mentioning

confidence: 99%